Pathophysiology and Pharmacological Targeting of Tumor-Induced Bone Disease: Current Status and Emerging Therapeutic Interventions

Author(s): V.T. Labropoulou, A.D. Theocharis, A. Symeonidis, S.S. Skandalis, N.K. Karamanos, H.P. Kalofonos

Journal Name: Current Medicinal Chemistry

Volume 18 , Issue 11 , 2011

Become EABM
Become Reviewer


Bone disease is a common complication of metastatic solid tumors but also of primary hematological malignancies such as multiple myeloma. Our understanding of the molecular mechanisms underlying the development of bone disease by solid tumors and multiple myeloma has been significantly improved. A complex inter-dependence exists between bone disease and malignant cell growth, creating a vicious cycle of extensive bone destruction and tumor progression. Although myeloma and solid tumors share a number of common molecular pathogenetic mechanisms, they involve distinct pathophysiological pathways, resulting in osteoclastic bone resorption and inhibition of bone formation. In this review, we analyze the molecular mechanisms, involved in tumor-induced bone disease and discuss the current therapeutic approaches and the most recent clinical developments of emerging targeted therapies.

Keywords: Bone disease, cancer, multiple myeloma, molecular targeting, osteoblasts, osteoclasts

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [1584 - 1598]
Pages: 15
DOI: 10.2174/092986711795471275
Price: $65

Article Metrics

PDF: 11